英克利西兰:高胆固醇血症的新药学方法
Stefania Angela Di Fusco1, Aldo Pietro Maggioni2, Chiara Bernelli3
1Emergency Department, Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, ASL Roma 1, 00135 Rome, Italy.
Reviews in cardiovascular medicine
|July 30, 2024
概括
英克利西兰是一种基因沉默疗法,在高胆固醇血症患者中显著降低了LDL胆固醇. 它的有效性和安全性概况表明,它是治疗高胆固醇的有希望的新疗法.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 高胆固醇血症的管理对心血管健康至关重要.
- 基因沉默技术提供了新的治疗途径.
- 英克利西兰向的是9型 (PCSK9) 蛋白转化酶亚素/素类型的mRNA.
研究的目的:
- 评估inclisiran在高胆固醇血症中的疗效和安全性.
- 评估inclisiran对低密度脂蛋白胆固醇 (LDL-C) 水平的影响.
- 在临床试验中将inclisiran与安慰剂进行比较.
主要方法:
- 第三阶段临床试验的元分析.
- 通过皮下注射给予inclisiran.
- 监测LDL-C水平和不良事件.
主要成果:
- 与安慰剂相比,18个月后LDL-C水平下降了51%.
- 在inclisiran和安慰剂组之间,可比的不良事件发生率.
- 在inclisiran组中,注射部位反应增加.
结论:
- 英克利西兰在高胆固醇血症中显示出显著的LDL-C降低.
- 这种药物是有效的,安全的,并且耐受良好.
- 由于Inclisiran的长时间效果和安全性,有利于在高胆固醇血症管理中使用.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
613
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
613
Cholesterol: Significance and Regulation
524
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
524
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
481
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
481
Drugs for Treatment of Constipation-Predominant IBS
151
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
151
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
165
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
165
Antihypertensive Drugs: Direct Renin Inhibitors
521
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
521


